Background

Pediatric acute lymphoblastic leukemia (ALL) patients have higher rates of second primary malignancies. There is limited data on second primary malignancies (SPM) among adult patients with ALL. This study was conducted to evaluate SPM in adult ALL patients using US Surveillance, Epidemiology and End Results (SEER) cancer registry database.

Methods

We analyzed the SEER 13 Registries using multiple primary standardized incidence ratio (MP-SIR) session. We analyzed secondary cancer rates among adult ALL patients during the period 1992 - 2010. We used SEER*Stat software provided by national cancer institute for statistical analysis.

Results

There were 3,259 adult (age ≥20 years) ALL patients reported in SEER database during 1992-2010. Among them, 65 ALL patients developed 75 second primary malignancies. Fifty-nine ALL patients developed 1 SPM each, 3 ALL patients developed 2 SPM each, 2 ALL patients developed 3 SPM each and 1 ALL patient developed 4 SPM. All site cancers were significantly higher among adult ALL patients compared to general population with observed/expected ratio (O/E): 1.47, p value< 0.05, an absolute excess risk of 24.43 per 10,000 populations. Similarly, oral cavity cancer, respiratory system cancer and hematological SPM were significantly higher in ALL patients than expected in general population. (Table)

Table

Second primary malignancy in ALL

Second Primary MalignancyPersons with ALL : 3,259 Person Years : 9,863.62
ObservedO/ECIsExcess RiskMean Age at Event
All Sites 75 1.47# 1.16-1.85 24.43 60.47 
All Sites excluding Non-Melonoma Skin 75 1.48# 1.16-1.85 24.64 60.47 
Oral Cavity and Pharynx 5.42# 2.18-11.17 5.79 59.18 
Small Intestine 9.55# 1.16-34.51 1.82 69.25 
Respiratory System 14 2.17# 1.18-3.63 7.64 70.47 
Lung and Bronchus 13 2.18# 1.16-3.73 7.14 69.61 
All Lymphatic and Hematopoietic Diseases 16 3.60# 2.06-5.85 11.72 47.83 
Leukemia 13 10.05# 5.35-17.87 11.87 49.94 
Non-Lymphocytic Leukemia 11 16.44# 8.21-29.42 10.47 50.22 
Acute Myeloid Leukemia 18.46# 7.42-38.03 6.71 52.37 
Chronic Myeloid Leukemia 16.17# 3.33-47.26 2.85 47.28 
Other Myeloid/Monocytic Leukemia 64.71# 1.64-360.53 44 
Second Primary MalignancyPersons with ALL : 3,259 Person Years : 9,863.62
ObservedO/ECIsExcess RiskMean Age at Event
All Sites 75 1.47# 1.16-1.85 24.43 60.47 
All Sites excluding Non-Melonoma Skin 75 1.48# 1.16-1.85 24.64 60.47 
Oral Cavity and Pharynx 5.42# 2.18-11.17 5.79 59.18 
Small Intestine 9.55# 1.16-34.51 1.82 69.25 
Respiratory System 14 2.17# 1.18-3.63 7.64 70.47 
Lung and Bronchus 13 2.18# 1.16-3.73 7.14 69.61 
All Lymphatic and Hematopoietic Diseases 16 3.60# 2.06-5.85 11.72 47.83 
Leukemia 13 10.05# 5.35-17.87 11.87 49.94 
Non-Lymphocytic Leukemia 11 16.44# 8.21-29.42 10.47 50.22 
Acute Myeloid Leukemia 18.46# 7.42-38.03 6.71 52.37 
Chronic Myeloid Leukemia 16.17# 3.33-47.26 2.85 47.28 
Other Myeloid/Monocytic Leukemia 64.71# 1.64-360.53 44 

Excess risk is per 10,000 US populations, Confidence intervals are 95%, # P value< 0.05.

Conclusions

Adult patients with ALL have higher rates of second primary malignancies compared to general population.

Disclosures:

No relevant conflicts of interest to declare.

Author notes

*

Asterisk with author names denotes non-ASH members.

Sign in via your Institution